R

Roche

Global pharmaceuticals and diagnostics company

IT Workspace Service Specialist

Full-TimeUpdated on 10/15/2026
No salary listed
Mid, Senior
Bachelor's
Taipei City, Taiwan
In Person
IT OperationsIT Project Management, IT Service Desk & End User Support

About the job

Requirements
  • Must have a Bachelor of Arts or Bachelor of Science degree in Computer Science, Engineering, or a related discipline, or recognition of prior working experience equivalent to that qualification.
  • Have 3 to 5 years of experience providing onsite and/or remote technical support to end users in PC and Mac environments across multiple domains.
  • Have experience and a proven track record of running high-performing environments, with professional experience in operational IT services across multiple technical fields.
  • Have knowledge of network concepts, including TCP/IP, Windows and Mac networking, wireless, and Ethernet.
  • Have a good understanding of web conferencing and mobile technologies, and audio-visual equipment as it relates to PC and Mac platforms.
  • Have experience with the ServiceNow ticketing system and troubleshooting hardware, software, and mobile devices.
  • Have excellent working knowledge of ITIL Incident Management processes in an IT service delivery environment.
Responsibilities
  • Monitor and maintain agreed business service levels for onsite support, including incident and request fulfilment according to ITIL best practices.
  • Achieve high customer satisfaction for End-User Services and ensure end users and local management are satisfied with IT support and services.
  • Support timely implementation of global and regional IT initiatives at the site.
  • Provide onsite service support and guidance for events and meetings, drive user experience, and promote best practices.
  • Interface with and support IT areas on infrastructure strategy and activities.
  • Provide local, regional, and global support for IT projects.
  • Ensure timely implementation of global, regional, and local initiatives and IT projects.
  • Propose opportunities to optimize service delivery using global guidelines as a reference.
  • Support incident and request management and measure performance against agreed service-level agreements.
  • Manage service providers and vendors, including contract management and service reviews.
  • Lead and deliver global and local network infrastructure, telephony, workplace, client hardware, and employee experience projects and deployments, including measuring solution success and adoption.
  • Manage and maintain the end-to-end hardware inventory process.
  • Work as part of an agile team focused on creating employee experiences through colleagues’ everyday interactions with workplace technology and digital services.
  • Lead and support business continuity activities.
  • Partner with business stakeholders to analyze business requirements, select solutions, deploy them, and contribute to marketing and change-management campaigns that encourage adoption.
  • Develop and execute communication strategies for IT services and projects.
  • Coordinate with IT areas on communications to end users.
  • Build communication pathways across squad and product teams, ensure messages are consistent across channels, and review communications before they are sent to business colleagues.
  • Create an effective IT experience that helps the business use the latest collaboration-suite ecosystem in line with agile principles.
  • Ensure new-hire onboarding readiness so employees gain value from Roche IT products.
  • Follow defined working processes and standards in daily duties.
  • Ensure compliance with global standards at the local level.
  • Continuously evaluate actual needs and reflect them in event forecasts.
Desired Qualifications
  • Understanding of Roche-supported operating systems, devices, and applications, including Google Suite applications and Microsoft Office, is an advantage.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.